Trial Profile
A 16-week, Multicentre, Randomised, Open-label, Parallel Group Study to Investigate the Efficacy and Safety Profiles of Repaglinide Monotherapy Compared to Gliclazide Monotherapy in Chinese Antidiabetic-naive Subjects With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary) ; Gliclazide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 13 Jan 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 13 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Oct 2010 Planned end date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.